Important molecular genetic markers of colorectal cancer
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
// Anna V. Kudryavtseva 1,2,* , Anastasia V. Lipatova 1,* , Andrew R. Zaretsky 3 , Alexey A. Moskalev 1 ,Maria S. Fedorova 1,2 ,Anastasiya S. Rasskazova 1 ,Galina A. Shibukhova 2 ,Anastasiya V. Snezhkina 1 , Andrey D. Kaprin 2 , Boris Y. Alekseev 2 ,Alexey A. Dmitriev 1 and George S. Krasnov 4,1 1 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia 2 National Medical Research Radiological Centre, Ministry of Healthcare of the Russian Federation, Moscow, Russia 3 Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia 4 Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia * These authors have contributed equally to this work Correspondence to: Anna V. Kudryavtseva, email: // Keywords : colorectal cancer, molecular markers, chromosomal instability, microsatellite instability, CpG island methylator phenotype Received : November 21, 2015 Accepted : May 21, 2016 Published : June 02, 2016 Abstract Colorectal cancer (CRC) ranks third in the incidences of cancer morbidity and mortality worldwide. CRC is rather heterogeneous with regard to molecular genetic characteristics and pathogenic pathways. A wide spectrum of biomarkers is used for molecular subtype determination, prognosis, and estimation of sensitivity to different drugs in practice. These biomarkers can include germline and somatic mutations, chromosomal aberrations, genomic abnormalities, gene expression alterations at mRNA or protein level and changes in DNA methylation status. In the present review we discuss the most important and well-studied CRC biomarkers, and their potential clinical significance and current approaches to molecular classification of colorectal tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 2×
“In CIN tumors, as a rule, there is a loss of 25-30% alleles [7].”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 1×
“The effectiveness of 5-fluorouracil therapy for patients with different CIMP status was also investigated in several studies, but the data are extremely contradictory, and that can be explained by methodological differences, primarily in gene panels that were used for the status determination [70, 106-108].”
MethodUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“BRAF mutations are rarely found in MSS or MSI-L tumors, which are characterized by poor prognosis [139, 161-163].”
BackgroundHaigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
Rudolph, K. L., Millard, M., Bosenberg, M. W., & DePinho, R. A. (2001) · Nature Genetics · doi:10.1038/88871 · Cited by 527 · cited 1×
“The study with Terc-deficient (telomerase RNA component) mice demonstrated association between telomere shortening and generation of intestinal carcinomas and microadenomas [41].”
Roles of p53, MYC and HIF-1 in regulating glycolysis–the seventh hallmark of cancer
Yeung, S. J., Pan, J., & Lee, M.-H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8224-x · Cited by 514
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486 · cited 1×
“The first study by Pietrantonio et al included 463 RAS-wt/BRAF-mut patients from 10 trials and demonstrated that the addition of cetuximab and panitumumab treatment for the BRAF-mut patients did not improve progression free, overall survival, overall response rates [166].”
Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012153 · Cited by 244 · cited 2×
“Mutation status of KRAS, NRAS, BRAF and PIK3CA genes can be used as a prognostic and especially as predictive marker: the presence of a mutation in the hotspots of any of these genes is associated with a potential resistance to inhibitors of receptor tyrosine kinases, as well as to monotherapy with mTOR inhibitors [12…”
BackgroundMao, C., Yang, Z. Y., Hu, X. F., Chen, Q., & Tang, J. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr464 · Cited by 188
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140 · cited 2×
“Active TP53 is maintained at low levels in the most of cells: once activated, TP53 upregulates E3 ubiquitin-ligase MDM2, which promote TP53 proteasomal degradation [213, 214].”
BackgroundBRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer
Barras, D. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25248 · Cited by 138
Cathomas, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00035 · Cited by 133 · cited 2×
“Against the background of absence of RAS mutations, PIK3CA substitutions in exon 20 seem to be marker of poor prognosis and potential inefficacy of anti-EGFR therapy [181-183].”
BackgroundFaber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124 · cited 2×
“In this case, combining mTOR and EGFR inhibition as well as simultaneous inhibition of mTOR and Bcl-2/Bcl-xL may improve therapeutic outcome in patients with KRASor BRAF-mutant CRC [143, 144].”
Chromosomal instability by β-catenin/TCF transcription in APC or β-catenin mutant cells
Aoki, K., Aoki, M., Sugai, M., Harada, N., Miyoshi, H., Tsukamoto, T., Mizoshita, T., Tatematsu, M., Seno, H., Chiba, T., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210141 · Cited by 82
Augustine, T. A., Baig, M., Sood, A., Budagov, T., Atzmon, G., Mariadason, J. M., Aparo, S., Maitra, R., & Goel, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.561 · Cited by 27
Cited by
Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location
Mima, K., Cao, Y., Chan, A. T., Qian, Z. R., Nowak, J. A., Masugi, Y., Shi, Y., Song, M., da Silva, A., Gu, M., et al. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.53 · Cited by 284
Jones, R. P., Sutton, P. A., Evans, J. P., Clifford, R., McAvoy, A., Lewis, J., Rousseau, A., Mountford, R., McWhirter, D., & Malik, H. Z. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.37 · Cited by 166
“A number of key genetic and epigenetic alterations have been identified (Colussi et al, 2013; Kudryavtseva et al, 2016), with early activating mutations in the KRAS gene reported in B40% of tumours (Downward, 2003).”
BackgroundIGF2BP2 promotes the progression of colorectal cancer through a YAP‐dependent mechanism
Cui, J., Tian, J., Wang, W., He, T., Li, X., Gu, C., Wang, L., Wu, J., & Shang, A. (2021) · Cancer Science · doi:10.1111/cas.15083 · Cited by 90
Metadata
- Authors
- Kudryavtseva, A. V., Lipatova, A. V., Zaretsky, A. R., Moskalev, A. A., Fedorova, M. S., Rasskazova, A. S., Shibukhova, G. A., Snezhkina, A. V., Kaprin, A. D., Alekseev, B. Y., Dmitriev, A. A., & Krasnov, G. S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-02
- Volume
- 7
- Issue
- 33
- Pages
- 53959-53983
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2418794140
- Cited by
- 114
- References
- 24
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.